Bausch + Lomb Corp
TSX:BLCO
Bausch + Lomb Corp
Founded in 1853, Bausch + Lomb Corp. began as a small optical goods store in Rochester, New York, eventually blossoming into a multinational eye health business. Over its long history, the company has established itself as a cornerstone in the realm of vision care, leveraging its deep expertise to innovate and expand its product offerings. Today, Bausch + Lomb operates through three primary business segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. In the Vision Care segment, it provides contact lenses, lens care products, and other related items, making it a trusted choice for consumers around the globe. The Ophthalmic Pharmaceuticals division addresses a broad spectrum of eye health needs, producing prescription and over-the-counter pharmaceuticals that target various eye conditions. Meanwhile, the Surgical segment offers a suite of ophthalmic surgical devices, designed for procedures ranging from cataract extraction to vitreoretinal surgery.
Bausch + Lomb generates revenue through a mix of consumer products and medical equipment. Their extensive contact lens product line caters to diverse needs – from daily disposables to specialized lenses for specific eye conditions, thereby capturing a significant portion of the eye care market. The company's pharmaceuticals and surgical tools not only complement its vision care products but also tap into the lucrative medical market, providing solutions for both medical professionals and their patients. By maintaining a robust portfolio that spans consumer goods and professional-grade equipment, Bausch + Lomb effectively positions itself as both a retail and medical partner, ensuring steady revenue streams from a global customer base. With a blend of research-driven innovation and strategic market positioning, Bausch + Lomb continues to cement its legacy as a leader in eye health.
Founded in 1853, Bausch + Lomb Corp. began as a small optical goods store in Rochester, New York, eventually blossoming into a multinational eye health business. Over its long history, the company has established itself as a cornerstone in the realm of vision care, leveraging its deep expertise to innovate and expand its product offerings. Today, Bausch + Lomb operates through three primary business segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. In the Vision Care segment, it provides contact lenses, lens care products, and other related items, making it a trusted choice for consumers around the globe. The Ophthalmic Pharmaceuticals division addresses a broad spectrum of eye health needs, producing prescription and over-the-counter pharmaceuticals that target various eye conditions. Meanwhile, the Surgical segment offers a suite of ophthalmic surgical devices, designed for procedures ranging from cataract extraction to vitreoretinal surgery.
Bausch + Lomb generates revenue through a mix of consumer products and medical equipment. Their extensive contact lens product line caters to diverse needs – from daily disposables to specialized lenses for specific eye conditions, thereby capturing a significant portion of the eye care market. The company's pharmaceuticals and surgical tools not only complement its vision care products but also tap into the lucrative medical market, providing solutions for both medical professionals and their patients. By maintaining a robust portfolio that spans consumer goods and professional-grade equipment, Bausch + Lomb effectively positions itself as both a retail and medical partner, ensuring steady revenue streams from a global customer base. With a blend of research-driven innovation and strategic market positioning, Bausch + Lomb continues to cement its legacy as a leader in eye health.
Revenue Growth: Bausch + Lomb reported third quarter revenue of $1.281 billion, up 6% year-over-year with growth across all business segments.
Pharma Standout: The Pharmaceuticals segment was a key driver, highlighted by $84 million in Miebo sales (up 71% YoY, 33% QoQ), and strong performances from Xiidra and the U.S. branded Rx business.
Contact Lens Momentum: The contact lens portfolio outpaced the market, with 6% growth and Daily SiHy up 24%; several other consumer brands posted double-digit gains.
Surgical Recovery: The Surgical segment rebounded from the enVista recall, with Q3 enVista sales reaching 82% of pre-recall levels and Envy at 91%.
Margin Expansion: Adjusted EBITDA margin improved sequentially by 400 basis points; SG&A expenses declined both sequentially and year-over-year, supporting profit growth.
Cash Flow Strength: Adjusted cash flow from operations was $161 million and adjusted free cash flow was $87 million in the quarter.
Guidance Update: Full-year revenue guidance was maintained at $5.05–$5.15 billion, while adjusted EBITDA guidance was raised at the lower end to $870–$910 million.
Strategic Focus: Management emphasized financial discipline, profitability, and sustainable growth, with more details to be shared at the November 13 Investor Day.
